{"url_path":"/sec/plx/8-k/2026-01-30/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-01-30","source_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-008410-index.html","accession_number":"0001104659-26-008410","cik":"0001006281","ticker":"PLX","issuer_name":"Protalix BioTherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-008410-index.html","primary_entity_key":"0001006281","primary_entity_name":"Protalix BioTherapeutics, Inc."},"word_count":304,"has_tables":true,"body_markdown":"false\n0001006281\n\n0001006281\n\n2026-01-30\n2026-01-30\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of**\n\n**the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of Earliest Event\nReported): January 30, 2026**\n\n \n\n \n\n \n\n**Protalix BioTherapeutics, Inc.**\n\n**(Exact name of registrant as specified\nin its charter)**\n\n \n\n \n\n \n\n**Delaware**\n \n**001-33357**\n \n**65-0643773**\n\n**(State or other jurisdiction**\n\n**of incorporation)**\n\n \n**(Commission File Number)**\n \n\n**(IRS Employer**\n\n**Identification No.)**\n\n \n\n**2 University Plaza**\n \n \n \n**07601**\n\n**Suite 100**\n \n \n \n**(Zip Code)**\n\n**Hackensack****, NJ**\n \n \n \n \n\n**(Address of principal executive offices)**\n \n \n \n \n\n \n\n**Registrant’s telephone number, including\narea code 201-696-9345**\n\n  \n\n**(Former name or former address, if changed\nsince last report.)**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction\nA.2. below):\n\n \n\n¨Written\ncommunication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities registered pursuant to Section\n12(b) of the Act:**\n\n \n\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\n\nCommon stock, $0.001 par value\nPLX\nNYSE American\n\n \n\nIndicate by check mark\nwhether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging growth\ncompany ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the\nregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ¨"}